Research programme: heparin-binding EGF-like factor inhibitors - Carna Biosciences
Latest Information Update: 16 Jul 2016
At a glance
- Originator Carna Biosciences
- Class
- Mechanism of Action Heparin-binding EGF-like growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Dermatitis; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Dermatitis in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Japan